Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Peptide Vaccines for Neoplasms
NCT04509167Phase 1Completed
- Sponsor
- Instituto de Medicina Regenerativa
- Start
- Aug 2020
- Primary completion
- Jun 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of personalized neoantigen peptide vaccine in Neoplasm, sponsored by Instituto de Medicina Regenerativa. Primary endpoints: Change from Baseline in WBC count at 12 months and Change from Baseline in RBC count at 12 months. Started Aug 2020; status: completed.
02
Drugs
personalized neoantigen peptide vaccine
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT04509167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04509167.